MAP2K2
MAP2K2 (mitogen-activated protein kinase kinase 2, also known as MEK2, MKK2 and PRKMK2) is a dual specificity protein kinase of the MAP kinase kinase family. It phosphorylates and activates the ERK MAP kinases and plays a critical role in mitogen growth factor signal transduction. Browse Assay Genie's current range of MAP2K2 research reagents below, or read on for the biology behind the target.
MAP2K2 catalyses the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases, which is why it is described as a dual specificity kinase. Through this activity it activates the ERK1 and ERK2 MAP kinases, and NCBI Gene describes it as phosphorylating and activating MAPK1/ERK2 and MAPK2/ERK3. The kinase itself is activated by Ser/Thr phosphorylation carried out by MAP kinase kinase kinases, placing it in the middle tier of the MAP kinase cascade.
MAP2K2 also acts on BRAF in a KSR1 or KSR2-dependent manner. By binding to KSR1 or KSR2, it releases the inhibitory intramolecular interaction between the KSR protein kinase and N-terminal domains. This promotes KSR-BRAF dimerisation and BRAF activation. The MAP2K2 protein is found in the cytoplasm and at membranes, and belongs to the protein kinase superfamily, STE Ser/Thr protein kinase family, MAP kinase kinase subfamily. HGNC places the MAP2K2 gene in the group of mitogen-activated protein kinase kinases, and a pseudogene on chromosome 7 has been identified.
Mutations in the MAP2K2 gene cause cardiofaciocutaneous (CFC) syndrome, a disease characterised by heart defects, cognitive disability and distinctive facial features similar to those seen in Noonan syndrome. Inhibition or degradation of this kinase has also been implicated in the pathogenesis of Yersinia infection and anthrax. The gene is also known by the aliases MEK2, MKK2 and PRKMK2, and orthologues are named Map2k2 in mouse and rat.
MAP2K2 is critical in mitogen growth factor signal transduction, linking upstream MAP kinase kinase kinases to ERK activation.
As a dual specificity kinase acting on Thr-Glu-Tyr motifs, MAP2K2 is a model for studying MAP kinase activation by phosphorylation.
MAP2K2 binding to KSR1 or KSR2 promotes KSR-BRAF dimerisation and BRAF activation, making it relevant to RAF regulation.
Mutations in MAP2K2 cause cardiofaciocutaneous syndrome, supporting studies of heart defects, cognitive disability and related Noonan-like conditions.
MAP2K2 is a dual specificity kinase that phosphorylates a threonine and a tyrosine in the Thr-Glu-Tyr sequence of MAP kinases, activating ERK1 and ERK2. It also promotes BRAF activation in a KSR1 or KSR2-dependent manner, contributing to mitogen growth factor signal transduction.
MAP2K2 is also called MEK2, MKK2 and PRKMK2. The HGNC name is mitogen-activated protein kinase kinase 2, and UniProt lists it as dual specificity mitogen-activated protein kinase kinase 2. Its enzyme classification is EC 2.7.12.2. Check the datasheet of any product for its validated reactivity.
Yes. Mutations in the MAP2K2 gene cause cardiofaciocutaneous syndrome, marked by heart defects, cognitive disability and distinctive facial features resembling Noonan syndrome. Inhibition or degradation of the kinase is also involved in the pathogenesis of Yersinia and anthrax. Mouse and rat carry the orthologue Map2k2.
Other MAP kinase kinases and MAP kinase kinase kinases that act in related signalling cascades.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P36507; product specifications from Assay Genie datasheets.